Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1759062 | 0.98 | CHRM5 (0.57) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Ammonia Solution, Strong SCHEMBL28330597 | 0.98 | CHRM1 (0.54) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL808458 | 0.80 | CHRM1 (0.54) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL3784397 | 0.79 | CHRM1 (0.48) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL7125777 | 0.79 | CHRM1 (0.54) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL16637633 | 0.77 | CHRM5 (0.56) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL28421705 | 0.77 | CHRM1 (0.46) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL28878493 | 0.77 | CHRM1 (0.50) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL2010713 | 0.77 | CES2 (0.37) | CYP2C19LMNATSHRSMN1; SMN2BLM | |
| SCHEMBL2241590 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | claimed |
| CN-113164043-A | Compositions and methods for glaucoma | 奥夫博医疗创新有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-1363877-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002070470-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | claimed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| US-20240245623-A1 | MODULAR TRANSDERMAL DELIVERY SYSTEM AND ASSOCIATED METHODS OF MANUFACTURE AND USE | PURE RATIOS HOLDING INC (US) | 2024-07-25 | — | — | US | disclosed |
| CN-116322332-A | Antipathogenic agent, antibacterial agent, antiviral agent, pathogen treatment device, method for producing antipathogenic agent, antibacterial method, virus inactivation method, and pathogen treatment method | 株式会社ACENET | 2023-06-23 | — | — | CN | disclosed |
| US-11583217-B2 | Neurophysiological data analysis using spatiotemporal parcellation | FIREFLY NEUROSCIENCE LTD. (IL) | 2023-02-21 | — | — | US | disclosed |
| CN-115161257-A | Improved differentiation process | 荷兰皇家科学院 | 2022-10-11 | — | — | CN | disclosed |
| CN-113081991-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-114585365-A | Use of parasympathomimetic agents alone or in combination with one or more alpha agonists to produce multifocal patients in pseudolens patients | 视觉治疗股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20030133985-A1 | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data | ASSERTIO THERAPEUTICS, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030104052-A1 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) | 2003-06-05 | — | — | US | disclosed |
| US-20030091630-A1 | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data | ASSERTIO THERAPEUTICS, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035029-A1 | FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM USING IN VITRO DISINTEGRATION TEST DATA | DEPOMED, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035041-A1 | GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT | DEPOMED, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030026850-A1 | N,N-dinitramide salts as solubilizing agents for biologically active agents | SRI INTERNATIONAL | 2003-02-06 | — | — | US | disclosed |
| WO-2003006371-A1 | N,N-DINITRAMIDE SALTS AS SOLUBILIZING AGENTS FOR BIOLOGICALLY ACTIVE AGENTS | SRI INTERNATIONAL (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002070470-A2 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030026850-A1 | N,N-dinitramide salts as solubilizing agents for biologically active agents | NPPA, NUCB2, DNPEP | CHRM1 2477/4885CHRM3 1645/4885CHRM5 1610/4885 |
| US-20030104052-A1 | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | SI, GIPR, MLNR | CHRM1 2179/4885CHRM3 2431/4885CHRM5 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.